David L. Veenstra, PharmD, PhD

Periodic reinterpretation of genetic sequencing results presents a challenge for developing transparent and systematic coverage and reimbursement policies.

This study critically assessed the published clinical and economic evidence supporting oncology orphan drugs marketed in the United States.